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Chikungunya virus (CHIKV) is an arthropod-borne virus (arbovirus) transmitted principally by mosquitoes.  
Chikungunya derives from a Makonde word meaning “that which bends,” describing the stooped appearance of persons suffering 
with the characteristic, severe arthralgia.  Outbreaks have been described in Africa, Southeast Asia, the Indian subcontinent and 
Indian Ocean islands.  A 2007 outbreak in northern Italy highlighted the risk of local transmission of the virus in the US via 
imported cases.  Like Italy, the US harbors competent mosquito vectors and naïve hosts, which creates a potential for emergence 
of CHIKV.  Given the risk of introduction, and the potential for significant morbidity due to CHIKV, timely diagnosis and alerting 
public health officials to suspect cases is critical to protect against a future outbreak in the US.  CDC and PAHO have developed a 




Chikungunya is an alphavirus of the family Togaviridae.  
It is composed of an enveloped, single-strand, positive 




  Aedes aegypti                Aedes albopictus 
       (“Asian Tiger Mosquito”)     
 
 
These mosquitoes can be identified by the white stripes on their black 
bodies and legs.  Although the mosquitos’ peak feeding time is dawn 
and dusk, they also are aggressive daytime biter. 
 
Hosts:  








Typically 3-7 days, with a range of 1-12 days.  
 
Symptoms/Presentation: 
1. Sudden onset of high fever (>102⁰F). 
2. Severe polyarthralgias mainly involving the distal 
joints of the extremities. 
3. Headache 
4. Myalgias 
5. Back pain 
6. Rash (~50% of cases) 
Symptoms typically resolve within 7-10 days.  The joint 




SYSTEM: CLINICAL MANIFESTATIONS: 
Neurological Meningoencephalitis, encephalopathy, seizures, Guillain-
Barre syndrome, paresis, palsies & neuropathy 
Ocular Optic neuritis, iridocyclitis, episcleritis, retinitis & uveitis 
Cardiovascular Myocarditis, pericarditis, heart failure, arrhythmias & 
hemodynamic instability 
Dermatological Photosensitive hyperpigmentation, intertriginous aphthous-
like ulcers & vesiculobullous dermatosis 
Renal Nephritis & acute renal failure 
Other Bleeding dyscrasias, pneumonia, respiratory failure, 
hepatitis, pancreatitis, syndrome of inappropriate secretion 
of antidiuretic hormone (SIADH) & hypoadrenalism 
These manifestations can be due to direct effects of the virus, 
immunological response to the virus, or drug toxicity. 
 
Differential Diagnosis: 
Diseases should be considered based upon epidemiological features 
such as place of residence, travel history and exposure. 
DISEASE/AGENT PRESENTATION 
Dengue fever Fever and two or more of the following: retro-orbital or 
ocular pain, headache, rash, myalgia, arthralgia, leucopenia, 
or hemorrhagic manifestations.  
Leptospirosis Severe myalgia localized to calf muscles with conjunctival 
congestion/or subconjunctival hemorrhage with or 
without jaundice or oliguria.  Consider history of contact 
with contaminated water. 
Post-infection 
arthritis 
Arthritis of one or more, typically larger joints due to an 
infectious disease such as Chlamydia, shigella, and 
gonorrhea.  Rheumatic fever is seen more commonly in 
children as migratory polyarthritis predominantly affecting 
large joints. Consider antistreptolysin O (ASO) titer and 
history of sore throat with Jones criteria for rheumatic 
fever. 
 
It is important to distinguish CHIKV from dengue, due to the 
potential for worse outcomes (including death) from dengue.  The 
two diseases can occur together in the same patient.  With CHIKV: 
 Pain is more intense and localized to the joints and tendons 
in CHIKV. 
 Onset of fever is more acute in CHIKV and is also shorter in 
duration. 












There is no specific antiviral drug treatment for CHIKV.  
Symptomatic treatment is recommended after excluding more 
serious conditions like dengue and bacterial infections. 
 
ACUTE DISEASE: 
Treatment is symptomatic or supportive: 
 Rest & Fluids 
 NSAIDs (to relieve arthritic component) 
 
For patients with severe joint pains unresponsive to NSAIDs: 
 Narcotics (e.g., morphine) 
 Short-term corticosteroids 
These can be used after evaluating the risk-benefit of treatment 
 
SUBACUTE & CHRONIC DISEASE: 
Convalescence can be prolonged, sometimes exceeding a year.  
Persistent joint pain may require pain management, including 
long-term anti-inflammatory therapy. 
 
For disabling peripheral arthritis refractory to other agents: 
 Intra-articular corticosteroids or topical NSAID 
therapies may be used to limit oral corticosteroid use. 
 Graduated physiotherapy 
 
Outcome: 
Mortality is rare and has been reported predominantly in the 
elderly and those who are immunosuppressed. 
 
Recovery without sequelae is expected; however chronic 
disease may occur and can continue for months to >1 year. 
 
Groups at highest risk of complications include: the elderly 
(>65 years) and those with comorbidities (hypertension, 
diabetes, etc.).  Neonates who acquire the infection 
antenatum also exhibit severe disease. 
 
DIAGNOSIS: 
Three main types of laboratory tests are used for diagnosing 
CHIK: 
 Virus isolation: Within the first 3 days of illness. 
 RT-PCR: Day 1-8, after onset of illness. 
 Serological assays for IgM/IgG: 4 days after illness 
and beyond. 
Since there is a range for when the virus is present in the blood, 
results from virus isolation and RT-PCR testing should not be 
used to exclude the diagnosis. 
 
Testing Locations:  
Currently testing is available at CDC’s Division of Vector-Borne 
Diseases (DVBD), a limited number of state health departments, 
and one commercial laboratory.  Contact your state health 










WHO TO TEST: 
 
A patient with acute onset of fever (>102⁰F) and severe 
arthralgia or arthritis not explained by other medical 
conditions, and who resides or has visited epidemic or 
endemic areas within two weeks prior to the onset of 
symptoms. 
 
Consider testing for CHIKV if there is a cluster of patients 
presenting with a febrile illness and severe joint pain. 
 
REPORTING: 
Report any person diagnosed with CHIK to local public 
health authorities to ensure local transmission has not 
occurred.   
 
If you suspect a cluster of CHIK cases, alert the health 
department even if testing results are not yet available.  
 
PREVENTION: 
There is currently no vaccine to prevent CHIK.  Reducing 
human vector contact is paramount. 
 
Prevention of mosquito bites: 
Acutely infected persons must avoid being bitten by Aedes 
mosquitoes, in order to prevent further transmission of the 
virus. 
 
Encourage the following measures to reduce the chance of 
being bitten: 
 Use mosquito repellents on exposed skin including: 
DEET, picaridin, IR3535 and oil of lemon 
eucalyptus.  
 Wear long-sleeved shirts and long pants if feasible. 
 Wear permethrin-treated clothing to repel and kill 
mosquitoes. 
 Use screens on windows and doors to exclude 
mosquitoes and when available, A/C can make 
households less hospitable to mosquitoes. 
 Participation in community and homeowner based 
vector-control strategies. 
 Ensure that water does not collect in 
containers around the home and 
community. 
 Chemical or biological control of larvae and 




FOR MORE INFORMATION VISIT: http://www.cdc.gov/chikungunya/ 
